Pfizer Zeldox Prolongs QT Interval 30 To 60 Msec In 11.6% Of Patients
Executive Summary
The oral formulation of Pfizer's Zeldox is associated with a QT prolongation of 30 to 60 milliseconds in 11.6% of patients, an update of Swedish labeling for the atypical antipsychotic states.
You may also be interested in...
Pfizer Expects Zeldox Labeling Negotiations To Continue Past September
Pfizer expects an "approvable" action from FDA in September to set up a final round of negotiations over labeling for the antipsychotic Zeldox, Pfizer Global R&D President John Niblack indicated during a July 27 investor conference call.
Zeldox QTc Prolongation Is Less Severe Than Serlect, Pfizer Tells Committee
The QTc prolongation associated with Pfizer's antipsychotic Zeldox does not lead to the same clinical events as seen with Abbott/Lundbeck's antipsychotic Serlect, Pfizer told the Psychopharmacological Drugs Advisory Committee July 19.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011